Clinical Parkinsonism Related Disorders最新文献

{"title":"Spinal and bulbar muscular atrophy in a patient with Parkinson's disease – Case report","authors":"Alexander Grotemeyer,&nbsp;Julie Rösch,&nbsp;Juergen Winkler,&nbsp;Martin Regensburger","doi":"10.1016/j.prdoa.2026.100484","DOIUrl":"10.1016/j.prdoa.2026.100484","url":null,"abstract":"<div><div>Spinal and bulbar muscular atrophy and Parkinson's disease rarely coexist. We describe a male patient presenting with parkinsonism, hyposmia, with DAT-SPECT deficits, responsive to dopaminergic therapy, preceding recognition of SBMA confirmed genetically. Dopamine agonist–associated dropped head syndrome unmasked underlying lower motor neuronopathy, highlighting diagnostic pitfalls and overlap between synucleinopathy and polyglutamine disease.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100484"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148642214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing daily step counts between a hip and wrist-worn device in adults with Parkinson's disease","authors":"Madison S. Smith,&nbsp;Kimberly J. Waddell,&nbsp;Stephanie Wood,&nbsp;James F. Morley","doi":"10.1016/j.prdoa.2026.100486","DOIUrl":"10.1016/j.prdoa.2026.100486","url":null,"abstract":"<div><h3>Introduction</h3><div>Wearable devices are increasingly used for measuring physical and physiological activity in daily life. Common appendicular symptoms of Parkinson's disease (PD), such as tremor and rigidity, could impact the accuracy of step counts when the device is worn in different body locations. Few studies have compared wrist- and hip-worn activity monitoring devices worn simultaneously in the home environment among adults with PD. The purpose of this study was to examine the agreement in daily step counts between two identical devices worn simultaneously at the wrist and hip in patients with PD.</div></div><div><h3>Methods</h3><div>Twenty-one individuals with PD wore Fitbit Inspire 2 devices simultaneously on the wrist and hip during waking hours for 7 days. Total step counts from both devices were obtained for each day. The agreement between devices was examined using an intraclass correlation coefficient. A Bland-Altman plot was used to visually examine agreement.</div></div><div><h3>Results</h3><div>The mean (SD) step count collected by the wrist-worn devices was 5221 (4345) and 5371 (3936) for the hip-worn devices, with an average difference of 150 steps. There was good overall agreement between the two devices with an intraclass correlation coefficient (ICC) of 0.84 (95% CI 0.78, 0.88), which was visualized with the Bland Altman plot.</div></div><div><h3>Conclusions</h3><div>In an independently ambulatory PD population, wrist- and hip-worn Fitbit devices showed good agreement when measuring daily steps, with the strength of agreement varying by overall step activity. These findings support the use of wrist worn activity devices in PD and their utility for capturing physiological metrics beyond step count, such as heart rate, activity intensity, and sleep quality, which cannot be captured with a hip-worn device.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100486"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148642215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of war on patients with Parkinson's disease","authors":"Mehri Salari,&nbsp;Masoud Etemadifar,&nbsp;Kamran Rezaei,&nbsp;Fatemeh Hojjatipour","doi":"10.1016/j.prdoa.2026.100491","DOIUrl":"10.1016/j.prdoa.2026.100491","url":null,"abstract":"","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100491"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148642652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of Parkinson’s disease – Global burden of disease research from 1990 to 2021 and future trend predictions","authors":"Sen Wang ,&nbsp;Yujie Che ,&nbsp;Yiqun Lin,&nbsp;Yukang Zhang,&nbsp;Wen He ,&nbsp;Wei Zhang","doi":"10.1016/j.prdoa.2026.100421","DOIUrl":"10.1016/j.prdoa.2026.100421","url":null,"abstract":"<div><h3>Background</h3><div>Parkinson’s disease (PD), a common neurodegenerative disorder, severely affects patients’ quality of life. This study aims to update the assessment of PD’s prevalence, incidence, mortality, and disability–adjusted life years (DALYs) from 1990 to 2021. Analyses were conducted at Socio-demographic Index (SDI), global, regional, and national levels, stratified by gender and age.</div></div><div><h3>Methods</h3><div>PD data from the Global Burden of Disease (GBD) 2021 database was extracted. Trends in age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and age-standardized DALY rate (ASDR) of PD were assessed, and estimated annual percentage change (EAPC) was calculated during the study period. Analyses were done by gender, age, GBD region, and SDI quintiles, using R statistical software for analyses and mapping.</div></div><div><h3>Results</h3><div>In 2021, the global burden of PD remained substantial. The number of prevalent PD cases grew from 3,148,394.56 in 1990 to 11,767,271.97 in 2021 (a 2.74-fold increase). Incident cases rose from 417,134.69 to 1,335,142.12 (a 2.20-fold increase). Males exhibited higher prevalence, incidence, and mortality rates than females across almost all age groups. High-SDI regions had higher ASPR, ASIR, and ASDR values than low-SDI regions. Countries and regions in Asia, particularly China and Japan, exhibited among the highest ASPR and ASIR globally. Projections indicate global ASPR and ASIR will continue to rise substantially over the next three decades (to 2050), with males exhibiting a faster rate of increase than females, while the ASMR is predicted to remain essentially stable.</div></div><div><h3>Conclusion</h3><div>This study systematically delineates the epidemiological landscape, temporal trends, and burden profiles of Parkinson’s disease across global, regional, gender-stratified, and age-specific populations, providing an evidence-based framework to guide precision prevention strategies and optimize healthcare resource prioritization.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"14 ","pages":"Article 100421"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145978294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of deep brain stimulation on non motor fluctuations in Parkinson’s disease (assessed with the NMF severity scale)","authors":"Christian Matta ,&nbsp;Camille Comet ,&nbsp;Corentin Gaillard ,&nbsp;Florent Faggianelli ,&nbsp;Stephan Grimaldi ,&nbsp;Tatiana Witjas ,&nbsp;Solène Ansquer ,&nbsp;Cécile Hubsch ,&nbsp;Mathieu Anheim ,&nbsp;Caroline Moreau ,&nbsp;Elodie Hainque ,&nbsp;Sophie Drapier ,&nbsp;Béchir Jarraya ,&nbsp;Chloé Laurencin ,&nbsp;Dominique Guehl ,&nbsp;Lucie Hopes ,&nbsp;Christine Brefel-Courbon ,&nbsp;Melissa Tir ,&nbsp;Ana Marques ,&nbsp;Tiphaine Rouaud ,&nbsp;Alexandre Eusebio","doi":"10.1016/j.prdoa.2026.100426","DOIUrl":"10.1016/j.prdoa.2026.100426","url":null,"abstract":"<div><h3>Background</h3><div>Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) is a well-established treatment for motor fluctuations (MF) in Parkinson’s disease (PD), but its impact on non-motor fluctuations (NMF) remains unclear. As NMFs are frequent, disabling, and affect quality of life, understanding their response to DBS is critical.</div></div><div><h3>Objectives</h3><div>To assess the presence of NMF after STN-DBS, identify preoperative factors of improvement, and compare NMF responses to DBS and levodopa.</div></div><div><h3>Methods</h3><div>This project is an ancillary study of the French multicenter PREDISTIM cohort. We used the validated Non-Motor Fluctuation Severity Scale (NMF2S) to evaluate NMFs one year after STN-DBS and before surgery when data were available. Evaluations were performed under standardized conditions (OFF-Dopa/OFF-Stim vs. OFF-Dopa/ON-Stim).</div></div><div><h3>Results</h3><div>We included 284 PD patients assessed one year after STN-DBS using the NMF2S scale. Preoperative data were available for 153 patients. Evaluations were performed under standardized stimulation conditions (OFF-Dopa/OFF-Stim vs. OFF-Dopa/ON-Stim).</div><div>STN-DBS led to a 41.1% reduction in NMF severity, with anxiety, concentration difficulties, and pain showing the most improvement. However, DBS effects were less pronounced than those of levodopa, especially for psychiatric symptoms. NMF improvement did not correlate with motor improvement. Among all preoperative variables, only the levodopa response in the cognitive domain was associated with post-DBS NMF benefit.</div></div><div><h3>Conclusions</h3><div>STN-DBS significantly improves NMFs, although to a lesser extent than levodopa. The dissociation between motor and non-motor responses underscores the need for specific markers to predict NMF outcomes. These findings support the integration of NMF assessment into DBS indications and patient selection.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"14 ","pages":"Article 100426"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146228891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-hypoxic chorea, dystonia, and parkinsonism: a case report and literature review","authors":"Mehri Salari ,&nbsp;Sara Kavianpoor ,&nbsp;Masoud Etemadifar ,&nbsp;Kamran Rezaei","doi":"10.1016/j.prdoa.2026.100432","DOIUrl":"10.1016/j.prdoa.2026.100432","url":null,"abstract":"","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"14 ","pages":"Article 100432"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147327438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-cultural adaptation, reliability, and preliminary construct validity of the Japanese version of the Parkinson’s disease pain classification system","authors":"Shuhei Ishida ,&nbsp;Tomohiko Nishigami ,&nbsp;Akira Mibu ,&nbsp;Masahiro Manfuku ,&nbsp;Hirofumi Yamashita ,&nbsp;Yuta Tomooka ,&nbsp;Norimasa Egusa ,&nbsp;Shigeto Moriwaki ,&nbsp;Kenichi Iwasa ,&nbsp;Keiko Yamada ,&nbsp;Satoshi Abe ,&nbsp;Sokichi Maniwa","doi":"10.1016/j.prdoa.2026.100441","DOIUrl":"10.1016/j.prdoa.2026.100441","url":null,"abstract":"<div><h3>Introduction</h3><div>Pain is a burdensome non-motor symptom of Parkinson’s disease (PD). However, its mechanisms are complex, complicating pain phenotyping. The PD Pain Classification System (PD-PCS) classifies pain mechanisms and their relationship with PD pathology. We developed a Japanese PD-PCS and evaluated its reliability and preliminary construct validity.</div></div><div><h3>Methods</h3><div>The PD-PCS was translated and adapted under developer supervision using an ISPOR-guided process. People with PD and chronic pain were recruited from two hospitals (n = 31). Intra- and inter-rater reliability were assessed with intraclass correlation coefficients (ICCs) for the PD-PCS pain score and κ for categorical classifications (95% CIs). The standard error of measurement (SEM) and the smallest detectable change (SDC) were calculated. Construct validity was examined using Spearman’s correlations between the PD-PCS pain score and the Brief Pain Inventory (BPI; average pain, interference).</div></div><div><h3>Results</h3><div>Cognitive debriefing identified wording issues that were resolved through revisions, resulting in the final Japanese version. Participants (n = 31) had a mean age of 70.5 ± 8.3 years, and 16 (51.6%) were men. The intra-rater reliability was good (ICC[3,1] = 0.768, 95% CI, 0.575–0.880; SEM 10.4; SDC_individual 29.0), and the inter-rater reliability was excellent (ICC[2,1] = 0.917, 95% CI, 0.836–0.959; SEM 5.8; SDC_individual 16.0). The agreement between pain mechanisms and PD-related pain classification was substantial to perfect (κ = 0.755–1.000). The PD-PCS pain score correlated with BPI average pain (ρ = 0.744) and interference (ρ = 0.747).</div></div><div><h3>Conclusion</h3><div>The Japanese PD-PCS demonstrated good to excellent reliability and preliminary construct validity, supporting its use in mechanism-informed pain classification in Japanese people with PD.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"14 ","pages":"Article 100441"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147702894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep brain stimulation in VPS13C-associated Parkinson’s disease: a longitudinal case study","authors":"Hiroyuki Sumikura ,&nbsp;Naoki Tani ,&nbsp;Hiroyo Yoshino ,&nbsp;Nobutaka Hattori ,&nbsp;Manabu Sakaguchi","doi":"10.1016/j.prdoa.2026.100445","DOIUrl":"10.1016/j.prdoa.2026.100445","url":null,"abstract":"","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"14 ","pages":"Article 100445"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147740266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between perceived stress and family quality of life: moderating impact of resilience among family caregivers of individuals with Parkinson's disease","authors":"Eun-Jeong Lee ,&nbsp;Heerak Choi ,&nbsp;Minju Lee ,&nbsp;Jessica Gabrielle Springer ,&nbsp;Yunjung Kim","doi":"10.1016/j.prdoa.2026.100459","DOIUrl":"10.1016/j.prdoa.2026.100459","url":null,"abstract":"<div><h3>Objective</h3><div>To identify key demographic covariates affecting family quality of life, examine associations among neuropsychiatric symptoms, perceived stress, resilience, and quality of life, and assess the moderating role of resilience in the relationship between perceived stress and family quality of life in family caregivers of individuals with Parkinson's disease.</div></div><div><h3>Design</h3><div>Survey.</div></div><div><h3>Setting</h3><div>Online survey platform, Prolific.</div></div><div><h3>Participants</h3><div>A total of 242 family caregivers of patients with PD, with the majority being children or grandchildren.</div></div><div><h3>Interventions</h3><div>Not applicable.</div></div><div><h3>Main Outcome Measure(s)</h3><div>The Family Quality of Life Scale, Perceived Stress Scale, Brief Resilience Scale, and Neuropsychiatric Inventory Questionnaire.</div></div><div><h3>Results</h3><div>Family quality of life was positively correlated with older age, male sex, married status, higher income, and additional family caregiving assistance. After controlling for demographic covariates, direct associations were found between neuropsychiatric symptoms and perceived stress (<em>β</em> = 0.20), between perceived stress and family quality of life (<em>β</em> = −0.39), and between resilience and family quality of life (<em>β</em> = 0.25). Resilience moderated the relationship between perceived stress and family quality of life (<em>β</em> = 0.13). Specifically, caregivers with low resilience showed the greatest declines in family quality of life as perceived stress increased, followed by those with mid-level of resilience. The slope for those with high resilience was not significant.</div></div><div><h3>Conclusions</h3><div>Enhancing caregivers' family quality of life requires multifaceted approaches targeting patient and caregiver needs. Patients' neuropsychiatric symptoms should be addressed through individualized medical or behavioral strategies. Caregivers may benefit from resilience-enhancing interventions to manage stress and improve family quality of life.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"14 ","pages":"Article 100459"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148230706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transition from subcutaneous levodopa/carbidopa (ND0612) to Foslevodopa/Foscarbidopa in advanced Parkinson's disease","authors":"Matteo Alessandro De Rosa,&nbsp;Dario Calisi,&nbsp;Mirella Russo,&nbsp;Astrid Thomas,&nbsp;Stefano Luca Sensi","doi":"10.1016/j.prdoa.2026.100466","DOIUrl":"10.1016/j.prdoa.2026.100466","url":null,"abstract":"<div><div><strong>Background</strong>: Continuous subcutaneous levodopa infusion is an established option for advanced Parkinson's disease (PD). Subcutaneous levodopa/carbidopa infusion (ND0612) and foslevodopa/foscarbidopa (ABBV-951) are available infusion systems; however, no clinical guidance exists regarding conversion between these treatments.</div><div><strong>Methods</strong>: We report two patients with advanced PD receiving ND0612 in combination with oral levodopa who underwent complete transition to ABBV-951. Initial foslevodopa/foscarbidopa dosing was estimated according to levodopa equivalent daily dose and subsequently titrated under close neurological supervision. Motor fluctuations, non-motor symptoms, quality of life, and infusion-site tolerability were evaluated at baseline and at 3-month follow-up using standardized clinical assessments.</div><div><strong>Results</strong>: Both transitions were completed within one day without acute adverse events. At three months, both patients showed a marked reduction in daily off time, improvement in dyskinesias and freezing of gait, and stabilization of sleep and behavioral symptoms. ABBV-951 demonstrated improved local tolerability, with no infusion-site complications observed during follow-up.</div><div><strong>Conclusions</strong>: Conversion from ND0612 to ABBV-951 appears feasible, and safe in advanced PD. These preliminary observations may provide practical insight in the absence of published data addressing this specific therapeutic transition.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100466"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13311910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148353315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}